These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10220611)

  • 1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data.
    Boyko WL; Glick HA; Schulman KA
    Am Heart J; 1999 May; 137(5):S115-9. PubMed ID: 10220611
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective.
    Boccuzzi SJ
    Am Heart J; 1999 May; 137(5):S120-2. PubMed ID: 10220612
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacoeconomics of ACE inhibitors in chronic heart failure.
    McMurray J; Davie A
    Pharmacoeconomics; 1996 Mar; 9(3):188-97. PubMed ID: 10160096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia.
    Butler JR; Fletcher PJ
    Aust N Z J Med; 1996 Feb; 26(1):89-95. PubMed ID: 8775534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The treatment of heart decompensation using angiotensin converting enzyme inhibitors. Pharmaco-economic aspects].
    Kulbertus H
    Rev Med Liege; 1998 May; 53(5):255-8. PubMed ID: 9689878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
    Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
    Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic significance of heart failure. An overview of costs and economics of therapy].
    Szucs TD; Sokolovic E
    Herz; 2000 Aug; 25(5):538-46. PubMed ID: 10993002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
    Szucs TD
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
    Grover SA; Coupal L; Lowensteyn I
    Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effective way forward for the management of the patient with heart failure.
    Giles T
    Cardiology; 1996; 87 Suppl 1():33-9. PubMed ID: 8681320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From cost of illness to cost-effectiveness in heart failure.
    Lévy E
    Eur Heart J; 1998 Dec; 19 Suppl P():P2-4. PubMed ID: 9886705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomes.
    Reeder CE; Gourley GA; Wurtzbacher JD; Reed P
    Am J Manag Care; 2000 Feb; 6(3 Suppl):S112-28, quiz S129-31. PubMed ID: 10977441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost and cost-effectiveness studies in heart failure research.
    Weintraub WS; Cole J; Tooley JF
    Am Heart J; 2002 Apr; 143(4):565-76. PubMed ID: 11923792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and economic factors in the treatment of congestive heart failure.
    Andrews R; Cowley AJ
    Pharmacoeconomics; 1995 Feb; 7(2):119-27. PubMed ID: 10155299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effective management of heart failure.
    Parmley WW
    Clin Cardiol; 1996 Mar; 19(3):240-2. PubMed ID: 8674263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.
    Erhardt L; Ball S; Andersson F; Bergentoft P; Martinez C
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):256-66. PubMed ID: 10170450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
    Szucs TD; Goedde M; Berger K; Kiowski W
    Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.
    van Hout BA; Wielink G; Bonsel GJ; Rutten FF
    Pharmacoeconomics; 1993 May; 3(5):387-97. PubMed ID: 10146889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.
    Schädlich PK; Huppertz E; Brecht JG
    Pharmacoeconomics; 1998 Dec; 14(6):653-69. PubMed ID: 10346417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.